Project Grant R43AI149798

The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...

The Department of the Army Medical Command awarded a $5.5 million Project Grant to Carogen Corporation to support the Combination of HBV Immunotherapy with shRNA-Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV from September 15, 2022 through September 14, 2025. This funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and develop...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This $4,728,039 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports Hbvtech, L.L.C, a minority-owned and self-certified small disadvantaged business, in developing a new treatment regimen for the durable elimination of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in chronic HBV infections. Through this multi-year (Jul 2025 - Jun 2029) project grant, Hbvtech will conduct research and...

This $3,878,480 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research by HDT Bio Corp to develop and characterize a novel muscle-localizing self-replicating RNA (RepRNA) vaccine platform delivered using lipid inorganic nanoparticle (LION) carriers. The key objectives of this 5-year project are to: 1) investigate the immunological function of skeletal muscle...

The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop complementary biotherapeutic delivery platforms to enable re-delivery of adeno-associated virus (AAV) gene therapies. The $1,095,274 award, with a performance period from August 1, 2024 to May 31, 2029, focuses on three key delivery platforms: 1) Targeted cell delivery of regulatory T cells to immunogenic cell death sites; 2)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...

This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...